Northpond Ventures

Slingshot Biosciences, Inc. is a manufacturer of biological products based in Emeryville, California, founded in 2012. The company focuses on developing next-generation synthetic cells aimed at enhancing diagnostics and therapeutics. By creating engineered synthetic cells, Slingshot Biosciences addresses challenges in drug research, particularly in measuring and standardizing cell analysis. Their innovations enable researchers to conduct advanced diagnostics without the limitations of cold-chain logistics, making their solutions more accessible. Additionally, the company is committed to developing products that target neglected and rare diseases, providing elegant and cost-effective solutions for common issues in research and development.

Totus Medicines specializes in developing innovative therapies to address previously untreatable diseases by harnessing advanced chemical biology techniques. The company utilizes a proprietary platform that enables high-throughput drug discovery, allowing it to screen billions of drug candidates against thousands of biological targets. This approach focuses on identifying effective molecules for traditionally challenging and undruggable targets, including those associated with cancer, Alzheimer's, infectious diseases, and the aging process. By converting genetic insights into viable therapeutic options, Totus Medicines aims to make a significant impact on the treatment landscape for various complex diseases.

Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, Kyverna employs advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells, which are responsible for the inflammation associated with these diseases. By addressing the root causes of autoimmune conditions, Kyverna aims to provide more effective and lasting solutions for patients suffering from these challenging health issues.

Telesis Bio is a biotech company established in 2013 and headquartered in San Diego, USA. It specializes in synthetic biology, providing researchers with tools to design, code, and create synthetic DNA and mRNA. The company focuses on enabling the rapid, accurate, and reproducible construction of high-quality synthetic genetic material for various applications in synthetic biology. Telesis Bio manufactures and sells laboratory equipment, including synthetic biology instruments, reagents, and related products. Its product offerings include the BioXp system, BioXp kits, benchtop reagents, and BioXp biofoundry services, all aimed at supporting researchers in their scientific endeavors.

Slingshot Biosciences, Inc. is a manufacturer of biological products based in Emeryville, California, founded in 2012. The company focuses on developing next-generation synthetic cells aimed at enhancing diagnostics and therapeutics. By creating engineered synthetic cells, Slingshot Biosciences addresses challenges in drug research, particularly in measuring and standardizing cell analysis. Their innovations enable researchers to conduct advanced diagnostics without the limitations of cold-chain logistics, making their solutions more accessible. Additionally, the company is committed to developing products that target neglected and rare diseases, providing elegant and cost-effective solutions for common issues in research and development.

Sound Agriculture uses molecular discovery to create climate-resilient crops, enhancing harvest yields for growers. They also use an innovative life science approach to sustainably increase farming productivity. The company was founded in 2013 and headquartered in Emeryville, California.

Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics.

EnPlusOne Biosciences specializes in developing innovative solutions for RNA therapeutics through its advanced synthesis platform. The company focuses on enzymatic-based RNA synthesis, which aims to address the limitations of traditional chemical synthesis methods. By tackling systemic challenges related to scaled production and access to novel therapeutic modifications, EnPlusOne enables the sustainable manufacturing of therapeutic RNA at a commercial scale. This approach positions the company to contribute significantly to the growing field of RNA-based therapeutics.

Vestaron Corporation specializes in the development, manufacture, and sale of peptide-based biologic crop protection products. Founded in 2005 and headquartered in Durham, North Carolina, with a research and development center in Kalamazoo, Michigan, Vestaron offers a range of bioinsecticides including Spear-T, Spear-Lep, and Leprotec, which target various pests in vegetables, fruits, and field crops. The company aims to enhance crop safety, efficacy, and sustainability by providing biopesticides that address resistance issues while ensuring safety for workers and the environment. Vestaron has received notable accolades for its innovative solutions, including the Bernard Blum Award and the Green Chemistry Challenge Award, recognizing its commitment to environmental stewardship and effective crop protection.

CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

Vizgen, Inc. is a biotechnology company focused on developing advanced tools for spatially resolved transcriptomic profiling, which enhances understanding of biological systems related to human health and disease. The company's primary offering, MERFISH, is a multiplexed single-molecule imaging technology that allows for the simultaneous measurement of RNA species' copy number and spatial distribution within individual cells. This technology facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights for research in fields such as oncology, immunology, neuroscience, infectious diseases, and regenerative medicine. Founded in 2019 and based in Cambridge, Massachusetts, Vizgen aims to empower medical researchers to explore complex biological questions on a systems scale through its innovative profiling solutions.

Transition Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in Cambridge, United Kingdom. Founded in 2020, the company specializes in the discovery, analysis, and modulation of biological condensates. It has developed a unique platform, known as Condensomics, which facilitates hypothesis-free drug discovery and diagnostics. Transition Bio utilizes advanced droplet microfluidic techniques and protein biophysics to characterize condensates with high precision, thereby creating extensive opportunities for drug development. The company's innovative approach aims to advance human health care by providing detailed insights into molecular structures.

Vestaron Corporation specializes in the development, manufacture, and sale of peptide-based biologic crop protection products. Founded in 2005 and headquartered in Durham, North Carolina, with a research and development center in Kalamazoo, Michigan, Vestaron offers a range of bioinsecticides including Spear-T, Spear-Lep, and Leprotec, which target various pests in vegetables, fruits, and field crops. The company aims to enhance crop safety, efficacy, and sustainability by providing biopesticides that address resistance issues while ensuring safety for workers and the environment. Vestaron has received notable accolades for its innovative solutions, including the Bernard Blum Award and the Green Chemistry Challenge Award, recognizing its commitment to environmental stewardship and effective crop protection.

Walking Fish Therapeutics is focused on creating cell-based therapeutics that utilize the unique capabilities of B cells to activate the immune system for cancer treatment. The company is developing a platform that aims to function as in vivo protein factories, producing replacement proteins for deficiency diseases and engineered antibodies. By harnessing the power of locally acting proteins, Walking Fish Therapeutics seeks to address serious health conditions across oncology, regenerative medicine, and autoimmune diseases, ultimately enabling healthcare providers to concentrate on innovative therapeutic approaches in these fields.

Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, Kyverna employs advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells, which are responsible for the inflammation associated with these diseases. By addressing the root causes of autoimmune conditions, Kyverna aims to provide more effective and lasting solutions for patients suffering from these challenging health issues.

Ori Biotech is a developer of a manufacturing platform designed to enhance access to lifesaving treatments through cell and gene therapies. The company has created a proprietary and flexible manufacturing system that automates and standardizes the production process, facilitating the transition of therapeutics from pre-clinical development to commercial-scale manufacturing. By integrating advanced hardware, software, data, and analytics, Ori Biotech's platform aims to increase throughput, improve quality, and reduce costs for therapeutics developers. This innovative approach is intended to accelerate the commercialization of cell and gene therapies, ultimately providing patients with a new generation of personalized and effective treatments.

Totus Medicines specializes in developing innovative therapies to address previously untreatable diseases by harnessing advanced chemical biology techniques. The company utilizes a proprietary platform that enables high-throughput drug discovery, allowing it to screen billions of drug candidates against thousands of biological targets. This approach focuses on identifying effective molecules for traditionally challenging and undruggable targets, including those associated with cancer, Alzheimer's, infectious diseases, and the aging process. By converting genetic insights into viable therapeutic options, Totus Medicines aims to make a significant impact on the treatment landscape for various complex diseases.

SimBioSys is focused on advancing cancer care through its innovative Computational Microscope, which combines cutting-edge simulation techniques with extensive experimental datasets. This technology allows researchers to examine the cancer microenvironment, gaining insights into tumor behavior, cell phenotypes, and interactions with surrounding tissues. By transforming comprehensive diagnostic datasets into personalized virtual tumors, SimBioSys enhances decision-making for healthcare providers and improves patient experiences in cancer treatment. Ultimately, the platform aims to facilitate a deeper understanding of cancer dynamics, enabling more effective and tailored therapeutic approaches.

Culture Biosciences, Inc. is a biomanufacturing company based in South San Francisco, California, that offers a cloud-based platform for scientists to conduct, monitor, and analyze bioreactor experiments. Founded in 2016, the company focuses on automating bioprocesses to help biotech firms optimize their manufacturing processes and expedite product development. By utilizing robotic sample handling and cloud data monitoring, Culture Biosciences enhances the efficiency of fermentation and bioreactor operations, allowing researchers to achieve results more rapidly than with traditional methods.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

DICE Therapeutics is a biopharmaceutical company that utilizes its proprietary technology platform to develop a pipeline of novel oral therapeutic candidates aimed at treating chronic diseases, particularly in the field of immunology. The company focuses on creating oral therapeutics that target well-established proteins, intending to achieve efficacy similar to existing systemic biologics. DICE's DELSCAPE platform is specifically designed to discover selective oral small molecules capable of modulating protein-protein interactions effectively. Its lead candidate, S011806, is an oral antagonist targeting interleukin-17, a key player in various immunological conditions. In addition to S011806, DICE is developing other oral therapeutic candidates that target α4ß7 integrin and αVß1/αVß6 integrin, aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Sound Agriculture uses molecular discovery to create climate-resilient crops, enhancing harvest yields for growers. They also use an innovative life science approach to sustainably increase farming productivity. The company was founded in 2013 and headquartered in Emeryville, California.

Slingshot Biosciences, Inc. is a manufacturer of biological products based in Emeryville, California, founded in 2012. The company focuses on developing next-generation synthetic cells aimed at enhancing diagnostics and therapeutics. By creating engineered synthetic cells, Slingshot Biosciences addresses challenges in drug research, particularly in measuring and standardizing cell analysis. Their innovations enable researchers to conduct advanced diagnostics without the limitations of cold-chain logistics, making their solutions more accessible. Additionally, the company is committed to developing products that target neglected and rare diseases, providing elegant and cost-effective solutions for common issues in research and development.

CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

Isolere Bio is a biotechnology company dedicated to simplifying the purification of biotherapeutics, particularly monoclonal antibodies and Adeno-Associated Viruses (AAV). Co-founded with the aim of enhancing global access to essential drugs, Isolere Bio develops innovative manufacturing technologies that utilize a straightforward Tangential Flow Filtration (TFF) setup. This approach facilitates a seamless transition from laboratory-scale processes to large-scale industrial production, thereby improving efficiency within the bioprocessing industry. As monoclonal antibodies continue to gain prominence as effective therapeutics and important research tools, Isolere Bio's work plays a crucial role in advancing the development of new diagnostics and treatments.

Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in the development and manufacture of reagents for marker multiplexing detection and analysis in the life sciences and biomedical fields. Founded in 2015, Ultivue focuses on tissue imaging and diagnostics, offering innovative technologies such as DNA-PAINT and DNA-Exchange. These technologies enable researchers to capture high-resolution microscopic images, facilitating a deeper understanding of biological processes and medical diagnostics. Ultivue's products are designed for use in fluorescent microscopy-based research, with the potential for significant applications in clinical diagnostics. The company's multiplex biomarker assays aid in tissue phenotyping and digital pathology, integrating validated antibodies and advanced analytics to support personalized medicine and enhance research discoveries related to complex tumor microenvironments.

Vizgen, Inc. is a biotechnology company focused on developing advanced tools for spatially resolved transcriptomic profiling, which enhances understanding of biological systems related to human health and disease. The company's primary offering, MERFISH, is a multiplexed single-molecule imaging technology that allows for the simultaneous measurement of RNA species' copy number and spatial distribution within individual cells. This technology facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights for research in fields such as oncology, immunology, neuroscience, infectious diseases, and regenerative medicine. Founded in 2019 and based in Cambridge, Massachusetts, Vizgen aims to empower medical researchers to explore complex biological questions on a systems scale through its innovative profiling solutions.

Vestaron Corporation specializes in the development, manufacture, and sale of peptide-based biologic crop protection products. Founded in 2005 and headquartered in Durham, North Carolina, with a research and development center in Kalamazoo, Michigan, Vestaron offers a range of bioinsecticides including Spear-T, Spear-Lep, and Leprotec, which target various pests in vegetables, fruits, and field crops. The company aims to enhance crop safety, efficacy, and sustainability by providing biopesticides that address resistance issues while ensuring safety for workers and the environment. Vestaron has received notable accolades for its innovative solutions, including the Bernard Blum Award and the Green Chemistry Challenge Award, recognizing its commitment to environmental stewardship and effective crop protection.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

DICE Therapeutics is a biopharmaceutical company that utilizes its proprietary technology platform to develop a pipeline of novel oral therapeutic candidates aimed at treating chronic diseases, particularly in the field of immunology. The company focuses on creating oral therapeutics that target well-established proteins, intending to achieve efficacy similar to existing systemic biologics. DICE's DELSCAPE platform is specifically designed to discover selective oral small molecules capable of modulating protein-protein interactions effectively. Its lead candidate, S011806, is an oral antagonist targeting interleukin-17, a key player in various immunological conditions. In addition to S011806, DICE is developing other oral therapeutic candidates that target α4ß7 integrin and αVß1/αVß6 integrin, aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Encodia, Inc., founded in 2015 and headquartered in San Diego, California, specializes in proteomics research and the development of innovative protein analysis technology. The company offers a platform that utilizes reverse-translation technology to convert peptide sequence information into DNA libraries, facilitating scalable and efficient protein sequencing. This capability enables researchers to analyze protein samples comprehensively, thereby advancing the field of personalized medicine. By democratizing access to detailed information on cellular processes, Encodia aims to accelerate the discovery of novel approaches to addressing challenging diseases.

Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. Established in 2017, the company aims to enhance treatment options for oncology and immunology by creating small, non-antibody protein scaffolds. These Centyrins can be engineered as multi-specific therapeutics, enabling innovative mechanisms of action. They are designed to improve efficacy and safety profiles for patients suffering from cancer and other serious diseases, while also facilitating the targeted delivery of complex drug payloads, including nucleic acids. Aro Biotherapeutics is committed to advancing its wholly-owned pipeline of Centyrins, contributing to the field of genetic medicines.

NanoView Biosciences is a biotechnology company that specializes in the development of technologies for the characterization of extracellular vesicles, particularly exosomes. Founded in 2015 and based in Boston, Massachusetts, the company utilizes its proprietary ExoView technology to provide high-throughput and cost-effective analysis solutions for life science researchers. NanoView's products, which include the ExoView R100 and ExoView tetraspanin, enable precise detection and multiparametric characterization of exosomes from complex biological samples such as blood, serum, plasma, and urine. In addition to its core products, the company offers custom assays, sample services, and a support platform to aid researchers in understanding the biological roles of exosomes and utilizing them as biomarkers for disease diagnosis, treatment, and monitoring.

GALT is a developer of a microbiological technology used to help cultivate and study bacteria and other microbes. Its platform develops novel technologies that vastly increase the ability to study microbes, the single most diverse and impact group of organisms on the planet that enable scientists to uncover deeper insights into microbiome-based applications in agriculture, human health, environment, and industry. The company's mission is to transform microbiome science through high-throughput microbial isolation and cultivation array system. General Automation Lab Technologies was established in 2014 and is headquartered in San Carlos, California.

Refeyn Ltd, founded in 2018 and based in Oxford, United Kingdom, specializes in mass photometry technology for the analysis of biomolecules. The company's flagship product, Refeyn One, employs single molecule light scattering to detect, image, and accurately determine the mass of biomolecules in solution. This innovative optical technology allows researchers to measure the mass of individual molecules in their native state without the necessity for labels, providing both quality-control instruments and advanced research tools. Refeyn's offerings enable scientists to conduct mass measurements across a range of biologically relevant concentrations, enhancing the capabilities of biomolecular analysis.

Ori Biotech is a developer of a manufacturing platform designed to enhance access to lifesaving treatments through cell and gene therapies. The company has created a proprietary and flexible manufacturing system that automates and standardizes the production process, facilitating the transition of therapeutics from pre-clinical development to commercial-scale manufacturing. By integrating advanced hardware, software, data, and analytics, Ori Biotech's platform aims to increase throughput, improve quality, and reduce costs for therapeutics developers. This innovative approach is intended to accelerate the commercialization of cell and gene therapies, ultimately providing patients with a new generation of personalized and effective treatments.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

Vizgen, Inc. is a biotechnology company focused on developing advanced tools for spatially resolved transcriptomic profiling, which enhances understanding of biological systems related to human health and disease. The company's primary offering, MERFISH, is a multiplexed single-molecule imaging technology that allows for the simultaneous measurement of RNA species' copy number and spatial distribution within individual cells. This technology facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights for research in fields such as oncology, immunology, neuroscience, infectious diseases, and regenerative medicine. Founded in 2019 and based in Cambridge, Massachusetts, Vizgen aims to empower medical researchers to explore complex biological questions on a systems scale through its innovative profiling solutions.

Codex DNA is a biology company helping researchers with the tools they need to securely design, code, and create synthetic DNA. The company is on a mission to help scientific researchers in both academic and commercial settings with the hardware, software, materials, and methodologies required to rapidly and accurately write large quantities of synthetic genes. To, in effect, build biology. Its gene synthesis portfolio reduces the turnaround time for synthesizing workflows from weeks and months to days and hours and includes the BioXp system, DNA services, Gibson Assembly reagents, and Vmax chemically competent cells. In addition to automating, speeding, and optimizing DNA design and synthesis, Codex DNA and the BioXp system ensure your designs stay in your hands, marrying speed and security for innovators in drug discovery, vaccine development, precision medicine, and beyond. Co-founded by Dan Gibson — the creator of the industry-standard Gibson Assembly methodology — Codex DNA is attempting nothing less than changing everything.

GALT is a developer of a microbiological technology used to help cultivate and study bacteria and other microbes. Its platform develops novel technologies that vastly increase the ability to study microbes, the single most diverse and impact group of organisms on the planet that enable scientists to uncover deeper insights into microbiome-based applications in agriculture, human health, environment, and industry. The company's mission is to transform microbiome science through high-throughput microbial isolation and cultivation array system. General Automation Lab Technologies was established in 2014 and is headquartered in San Carlos, California.

Codex DNA is a biology company helping researchers with the tools they need to securely design, code, and create synthetic DNA. The company is on a mission to help scientific researchers in both academic and commercial settings with the hardware, software, materials, and methodologies required to rapidly and accurately write large quantities of synthetic genes. To, in effect, build biology. Its gene synthesis portfolio reduces the turnaround time for synthesizing workflows from weeks and months to days and hours and includes the BioXp system, DNA services, Gibson Assembly reagents, and Vmax chemically competent cells. In addition to automating, speeding, and optimizing DNA design and synthesis, Codex DNA and the BioXp system ensure your designs stay in your hands, marrying speed and security for innovators in drug discovery, vaccine development, precision medicine, and beyond. Co-founded by Dan Gibson — the creator of the industry-standard Gibson Assembly methodology — Codex DNA is attempting nothing less than changing everything.

Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in the development and manufacture of reagents for marker multiplexing detection and analysis in the life sciences and biomedical fields. Founded in 2015, Ultivue focuses on tissue imaging and diagnostics, offering innovative technologies such as DNA-PAINT and DNA-Exchange. These technologies enable researchers to capture high-resolution microscopic images, facilitating a deeper understanding of biological processes and medical diagnostics. Ultivue's products are designed for use in fluorescent microscopy-based research, with the potential for significant applications in clinical diagnostics. The company's multiplex biomarker assays aid in tissue phenotyping and digital pathology, integrating validated antibodies and advanced analytics to support personalized medicine and enhance research discoveries related to complex tumor microenvironments.

Deep Lens, Inc. is a technology company based in Columbus, Ohio, that specializes in digital pathology and healthcare data platforms. Founded in 2005, it develops the VIPER platform, which utilizes artificial intelligence for image detection and workflow support. The platform facilitates collaboration among pathology groups, enhancing cancer research and enabling healthcare providers to match patients with appropriate clinical trials and precision therapies. By integrating cloud storage and APIs for third-party AI models, Deep Lens streamlines processes for pathologists and physicians, ultimately improving patient treatment options. The company's focus on compliance and efficient data handling positions it as a valuable player in the healthcare technology sector.

Candel Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing cancer immunotherapies aimed at enhancing the quality of life for cancer patients and their families. The company specializes in low-toxicity viral immunotherapies that target the prevention of cancer recurrence and progression, particularly for less aggressive cancers such as newly diagnosed prostate cancer. Candel has developed two clinical-stage platforms utilizing novel, genetically modified constructs of adenovirus and herpes simplex virus (HSV). These innovative approaches enable physicians to improve patient outcomes and facilitate quicker recovery, marking a significant advancement in cancer treatment.

Teckro, Inc. is a life science technology company based in Limerick, Ireland, with additional offices in Dublin and Nashville. Founded in 2015, Teckro focuses on transforming clinical trials by providing a software platform that connects all stakeholders involved in clinical research, including pharmaceutical companies, clinical researchers, and study teams. The platform enables instant access to relevant information for every active member of a study, facilitating seamless communication and collaboration. By utilizing information retrieval and machine learning technologies, Teckro streamlines the clinical development process, enhancing the speed and accuracy of trials. The company's solutions ultimately aim to expedite the development of drugs and treatments for complex diseases, thereby improving outcomes in clinical research.

NanoView Biosciences is a biotechnology company that specializes in the development of technologies for the characterization of extracellular vesicles, particularly exosomes. Founded in 2015 and based in Boston, Massachusetts, the company utilizes its proprietary ExoView technology to provide high-throughput and cost-effective analysis solutions for life science researchers. NanoView's products, which include the ExoView R100 and ExoView tetraspanin, enable precise detection and multiparametric characterization of exosomes from complex biological samples such as blood, serum, plasma, and urine. In addition to its core products, the company offers custom assays, sample services, and a support platform to aid researchers in understanding the biological roles of exosomes and utilizing them as biomarkers for disease diagnosis, treatment, and monitoring.

GALT is a developer of a microbiological technology used to help cultivate and study bacteria and other microbes. Its platform develops novel technologies that vastly increase the ability to study microbes, the single most diverse and impact group of organisms on the planet that enable scientists to uncover deeper insights into microbiome-based applications in agriculture, human health, environment, and industry. The company's mission is to transform microbiome science through high-throughput microbial isolation and cultivation array system. General Automation Lab Technologies was established in 2014 and is headquartered in San Carlos, California.

DICE Therapeutics is a biopharmaceutical company that utilizes its proprietary technology platform to develop a pipeline of novel oral therapeutic candidates aimed at treating chronic diseases, particularly in the field of immunology. The company focuses on creating oral therapeutics that target well-established proteins, intending to achieve efficacy similar to existing systemic biologics. DICE's DELSCAPE platform is specifically designed to discover selective oral small molecules capable of modulating protein-protein interactions effectively. Its lead candidate, S011806, is an oral antagonist targeting interleukin-17, a key player in various immunological conditions. In addition to S011806, DICE is developing other oral therapeutic candidates that target α4ß7 integrin and αVß1/αVß6 integrin, aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.